Drug profile · INN
bivalirudin
BIVALIRUDIN ARX
bivalirudin (BIVALIRUDIN ARX) is a thrombin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — bivalirudin
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- INJECTION
- Patents
- 3
- Programs
- 1
- Data quality
- 0.89
Quick answer
bivalirudin (BIVALIRUDIN ARX) is a thrombin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Thrombin inhibitor
Primary target: Prothrombin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is bivalirudin?
bivalirudin (BIVALIRUDIN ARX) is a thrombin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for bivalirudin?
BIVALIRUDIN ARX is a marketed brand name for bivalirudin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bivalirudin?
bivalirudin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.